Randomized, controlled trial efficacy of pneumococcal conjugate vaccine against otitis media among navajo and white mountain apache infants

Katherine L. O'Brien; Angeline B. David; Aruna Chandran; Lawrence H. Moulton; Raymond Reid; Robert Weatherholtz; Mathuram Santosham

doi:10.1097/INF.0b013e318159228f

Randomized, controlled trial efficacy of pneumococcal conjugate vaccine against otitis media among navajo and white mountain apache infants

Katherine L. O'Brien, Angeline B. David, Aruna Chandran, Lawrence H. Moulton, Raymond Reid, Robert Weatherholtz, Mathuram Santosham

Research output: Contribution to journal › Article › peer-review

46 Scopus citations

Abstract

We report the phase III trial efficacy of 7-valent pneumococcal conjugate vaccine against clinical and culture proven otitis media (OM) among Navajo and White Mountain Apache infants. Efficacy was -0.4% (95% CI: -19.4 to 15.6) for clinically-diagnosed OM, 5.1% (95% CI: -51.5 to 40.6) for severe OM, and 64% (95% CI: -34% to 90%) for vaccine serotype pneumococcal OM suggesting that this vaccine is efficacious for pneumococcal OM in this high risk population.

Original language	English (US)
Pages (from-to)	71-73
Number of pages	3
Journal	Pediatric Infectious Disease Journal
Volume	27
Issue number	1
DOIs	https://doi.org/10.1097/INF.0b013e318159228f
State	Published - Jan 2008

Keywords

American Indian
Otitis media
Pneumococcal conjugate vaccine
Pneumococcus
Randomized clinical trial
Streptococcus pneumonia

ASJC Scopus subject areas

Pediatrics, Perinatology, and Child Health
Microbiology (medical)
Infectious Diseases

Access to Document

10.1097/INF.0b013e318159228f

Cite this

@article{db4af472b47c4fa8b008964c436bce96,

title = "Randomized, controlled trial efficacy of pneumococcal conjugate vaccine against otitis media among navajo and white mountain apache infants",

abstract = "We report the phase III trial efficacy of 7-valent pneumococcal conjugate vaccine against clinical and culture proven otitis media (OM) among Navajo and White Mountain Apache infants. Efficacy was -0.4% (95% CI: -19.4 to 15.6) for clinically-diagnosed OM, 5.1% (95% CI: -51.5 to 40.6) for severe OM, and 64% (95% CI: -34% to 90%) for vaccine serotype pneumococcal OM suggesting that this vaccine is efficacious for pneumococcal OM in this high risk population.",

keywords = "American Indian, Otitis media, Pneumococcal conjugate vaccine, Pneumococcus, Randomized clinical trial, Streptococcus pneumonia",

author = "O'Brien, {Katherine L.} and David, {Angeline B.} and Aruna Chandran and Moulton, {Lawrence H.} and Raymond Reid and Robert Weatherholtz and Mathuram Santosham",

note = "Funding Information: Financial support for the American Indian PnCRM7 Efficacy Trial was from Wyeth Vaccines, National Institutes of Health, World Health Organization, The National Vaccine Program Office, and the Centers for Disease Control and Prevention. ",

year = "2008",

month = jan,

doi = "10.1097/INF.0b013e318159228f",

language = "English (US)",

volume = "27",

pages = "71--73",

journal = "Pediatric Infectious Disease Journal",

issn = "0891-3668",

publisher = "Lippincott Williams and Wilkins",

number = "1",

}

TY - JOUR

T1 - Randomized, controlled trial efficacy of pneumococcal conjugate vaccine against otitis media among navajo and white mountain apache infants

AU - O'Brien, Katherine L.

AU - David, Angeline B.

AU - Chandran, Aruna

AU - Moulton, Lawrence H.

AU - Reid, Raymond

AU - Weatherholtz, Robert

AU - Santosham, Mathuram

N1 - Funding Information: Financial support for the American Indian PnCRM7 Efficacy Trial was from Wyeth Vaccines, National Institutes of Health, World Health Organization, The National Vaccine Program Office, and the Centers for Disease Control and Prevention.

PY - 2008/1

Y1 - 2008/1

N2 - We report the phase III trial efficacy of 7-valent pneumococcal conjugate vaccine against clinical and culture proven otitis media (OM) among Navajo and White Mountain Apache infants. Efficacy was -0.4% (95% CI: -19.4 to 15.6) for clinically-diagnosed OM, 5.1% (95% CI: -51.5 to 40.6) for severe OM, and 64% (95% CI: -34% to 90%) for vaccine serotype pneumococcal OM suggesting that this vaccine is efficacious for pneumococcal OM in this high risk population.

AB - We report the phase III trial efficacy of 7-valent pneumococcal conjugate vaccine against clinical and culture proven otitis media (OM) among Navajo and White Mountain Apache infants. Efficacy was -0.4% (95% CI: -19.4 to 15.6) for clinically-diagnosed OM, 5.1% (95% CI: -51.5 to 40.6) for severe OM, and 64% (95% CI: -34% to 90%) for vaccine serotype pneumococcal OM suggesting that this vaccine is efficacious for pneumococcal OM in this high risk population.

KW - American Indian

KW - Otitis media

KW - Pneumococcal conjugate vaccine

KW - Pneumococcus

KW - Randomized clinical trial

KW - Streptococcus pneumonia

UR - http://www.scopus.com/inward/record.url?scp=37549065537&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=37549065537&partnerID=8YFLogxK

U2 - 10.1097/INF.0b013e318159228f

DO - 10.1097/INF.0b013e318159228f

M3 - Article

C2 - 18162944

AN - SCOPUS:37549065537

SN - 0891-3668

VL - 27

SP - 71

EP - 73

JO - Pediatric Infectious Disease Journal

JF - Pediatric Infectious Disease Journal

IS - 1

ER -

Randomized, controlled trial efficacy of pneumococcal conjugate vaccine against otitis media among navajo and white mountain apache infants

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this